Rapid infusion of sodium valproate in acutely ill children

Area of Science:

• Pediatric Pharmacology
• Clinical Pharmacy
• Neuropharmacology

Background:

• Sodium valproate is an antiepileptic drug used for various seizure types.
• Rapid infusion protocols are sometimes necessary in acute care settings.
• Understanding drug concentrations and safety profiles in specific pediatric populations is crucial.

Purpose of the Study:

• To assess the clinical safety of rapid sodium valproate infusion in hospitalized, acutely ill children.
• To measure total and unbound valproic acid plasma concentrations following rapid infusion.
• To compare these concentrations with those in relatively healthy epilepsy patients.

Main Methods:

• Four acutely ill children (5-15 years) received sodium valproate doses (8.3-15.4 mg/kg) over <=15 minutes.
• Clinical safety was monitored through vital signs and adverse event observation.
• Plasma concentrations of total and unbound valproic acid were measured at pre-infusion, 0.5 hours, and 6 hours post-infusion.

Main Results:

• No clinically significant changes in vital signs or adverse events were observed.
• Total and unbound valproic acid concentrations peaked at 0.5 hours post-infusion.
• Unbound valproic acid concentrations were higher in acutely ill children compared to healthy epilepsy patients and unpredictable from total concentrations.

Conclusions:

• Rapid administration of sodium valproate can be safely performed in acutely ill pediatric patients.
• Higher unbound valproic acid concentrations in this population warrant further investigation.
• Current predictive models for valproic acid concentrations may not apply to acutely ill children.